TherapeuticsMD Inc (TXMD)

7.04
0.28 4.10
AMEX : Health Care
Prev Close 6.77
Open 6.65
Day Low/High 6.57 / 7.10
52 Wk Low/High 5.18 / 11.26
Volume 1.48M
Avg Volume 2.14M
Exchange AMEX
Shares Outstanding 197.52M
Market Cap 1.31B
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Stocks Under $10 Weekly Summary

We picked up more Abraxas Petroleum on weakness, while the market rebounded slightly after the FOMC announced the anticipated quarter-point rate hike.

TherapeuticsMD Announces Presentation At The Oppenheimer 27th Annual Healthcare Conference On March 22

TherapeuticsMD Announces Presentation At The Oppenheimer 27th Annual Healthcare Conference On March 22

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that the company's CEO Robert Finizio will present at the Oppenheimer 27 th Annual Healthcare Conference in New York on March...

Stocks Under $10 Weekly Summary

We bulked up on Abraxas Petroleum and Yamana Gold on weakness, as the markets pulled back and investors positioned for next week’s FOMC meeting.

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

Finding the stocks that have changed direction.

TherapeuticsMD Announces Presentation At Cowen And Company 37th Annual Healthcare Conference On March 7

TherapeuticsMD Announces Presentation At Cowen And Company 37th Annual Healthcare Conference On March 7

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that the company's CEO Robert Finizio will present at the Cowen and Company 37 th Annual Healthcare Conference in Boston March...

Stocks Under $10 Weekly Summary

We booked some profits in Huntington Bancshares and Builders FirstSource, while markets digested the likelihood of a March rate hike.

Stocks Under $10 Weekly Summary

We opened a new position in Abraxas Petroleum on its above-average growth potential, as stocks faced selling pressure this week.

TherapeuticsMD Rating Reaffirmed After Earnings

The timeline for its two lead hormone therapy treatments remains on pace.

TherapeuticsMD Announces Fourth Quarter And Full-Year 2016 Financial Results

TherapeuticsMD Announces Fourth Quarter And Full-Year 2016 Financial Results

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced its fourth quarter and full-year financial results for 2016.

TherapeuticsMD Enters Oversold Territory

TherapeuticsMD Enters Oversold Territory

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TherapeuticsMD Announces Webcast Of Investor Day On March 1

TherapeuticsMD Announces Webcast Of Investor Day On March 1

TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women's healthcare company, today announced webcast details for its Investor Day on Wednesday, March 1, 2017, in New York City.

5 Ways Allergan Can Keep Up Momentum

5 Ways Allergan Can Keep Up Momentum

Allergan's most-recent quarterly financial report for Q4/2016 showed solid results.

Stocks Under $10 Weekly Summary

We closed out our position in OraSure Technologies for an average gain of 105% gain.

TherapeuticsMD To Host Fourth Quarter And Year End 2016 Financial Results Conference Call And Webcast On February 23

TherapeuticsMD To Host Fourth Quarter And Year End 2016 Financial Results Conference Call And Webcast On February 23

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that it will host a conference call and live audio webcast to discuss its fourth quarter and year end 2016 financial and...

Stocks Under $10 Weekly Summary

We used some of the proceeds to boost our stake in Jive Software this week. In addition, we initiated a position in drug-delivery system developer, Antares Pharma.

Stocks Under $10 Weekly Summary

We used a price decline to add to our position in TherapeuticsMD this week.

September 15th Options Now Available For TherapeuticsMD (TXMD)

September 15th Options Now Available For TherapeuticsMD (TXMD)

Investors in TherapeuticsMD, Inc. saw new options become available today, for the September 15th expiration.

Adding to TherapeuticsMD on Weakness

We maintain our $12.50 price target on this stock.

Stocks Under $10 Portfolio: Consumer Staples Overbought

Stocks Under $10 Portfolio: Consumer Staples Overbought

This week we'll get regional economic and housing data, a GDP report plus fourth-quarter earnings.

Stocks Under $10 Weekly Summary

We’d look to purchase Builders FirstSource, Jive Software and TherapeuticsMD on near-term declines.

TherapeuticsMD Announces Investor Day On March 1

TherapeuticsMD Announces Investor Day On March 1

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that the company will host an Investor Day on Wednesday, March 1, 2017, in New York City.

Stocks Under $10 Weekly Summary

We would consider adding to TherapeuticsMD on the next market decline and booking profits in ON Semiconductor into a rally.

TherapeuticsMD Announces Publication Of Two Manuscripts On The Rejoice Trial For TX-004HR In Leading Peer-Reviewed Medical Journal

TherapeuticsMD Announces Publication Of Two Manuscripts On The Rejoice Trial For TX-004HR In Leading Peer-Reviewed Medical Journal

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced the publication of two manuscripts detailing results of the company's phase 3 Rejoice Trial in Menopause: The Journal of The...

Stocks Under $10 Weekly Summary

We didn't trade in the model portfolio this week, but several of our holdings made big moves so far this year.

TherapeuticsMD Posts Strong Gains

TherapeuticsMD is up 9.7% in the first two trading days of 2017, and we're maintaining our $12.50 price target.

'Mad Money' Lightning Round: Jim Cramer Sees Opportunity in Sirius and Medtronic

'Mad Money' Lightning Round: Jim Cramer Sees Opportunity in Sirius and Medtronic

Sirius, Medtronic and Carlyle could be money makers in 2017, says Jim Cramer.

Cramer's 'Mad Money' Recap (Tuesday 1/3/17): Better Buying Opportunities Are Lurking

Cramer's 'Mad Money' Recap (Tuesday 1/3/17): Better Buying Opportunities Are Lurking

Jim Cramer outlines what he thinks this market needs to keep the Trump rally rolling in 2017.

TherapeuticsMD To Present At 35th Annual J.P. Morgan Healthcare Conference On January 11

TherapeuticsMD To Present At 35th Annual J.P. Morgan Healthcare Conference On January 11

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that the company will present at the 35 th Annual J.